Project Grant R44CA314776
Award Date 9/1/26
Completion Date 8/31/28
Dollars Obligated $1.1M
Federal Agency
Awardee
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Half Moon Bay, CA, USA
Similar Awards
- The National Cancer Institute awarded $1,057,841 to Pathware Inc. on September 1, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) as a Small Business Innovation Research Direct-to-Phase II grant (R44CA302204). Pathware is developing an automated imaging platform combining coded ptychography with artificial intelligence algorithms to evaluate the diagnostic adequacy of unstained lung biopsy samples at the point of care. The system provides rapid on-site evaluation...
- The National Institute of Biomedical Imaging and Bioengineering awarded Brigham and Women's Hospital Inc. $268,500 on August 20, 2026, to develop and validate a biomimetic palpation system for intraoperative lung nodule localization and margin assessment during minimally invasive lung cancer surgery. The award funds development of BiopalP, a novel tactile-sensing device that integrates multimodal haptic feedback with deep learning algorithms to enable surgeons to accurately localize small lung...
- The National Cancer Institute awarded The Leland Stanford Junior University $626,743 on July 7, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop intraoperative molecular imaging of lung cancer using panitumumab-IRDYE800 (PAN800). The funded research addresses accurate tumor localization during lung cancer surgery, particularly for small, less dense, or deep tumors and minimally invasive surgical approaches where palpation is difficult. Current techniques...
- Federal Grant Award Summary Cereus Diagnostics Corp. received a $764,448 Project Grant from the National Cancer Institute under the Cancer Detection and Diagnosis Research Program (CFDA 93.394) awarded on August 1, 2025, with completion targeted for July 31, 2028. The company is developing LUNG-FAST (Fragment Analysis, SNP, and Translocations), a rapid polymerase chain reaction (PCR)-based diagnostic test designed to detect clinically actionable lung cancer mutations including EGFR, KRAS, ALK,...
- The National Cancer Institute awarded The Washington University $645,414 on June 18, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop integrin-targeted positron emission tomography imaging and therapeutics for predicting and treating radiation-induced pulmonary fibrosis in lung cancer patients. The project uses mouse models of radiation-induced pulmonary fibrosis to test two complementary approaches: non-invasive αvβ6 PET imaging to detect early...
- This $399,499 Project Grant award from the National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), supports the development of Liquid Biotech's TELOMESCAN circulating tumor cell (CTC) assay for monitoring non-small cell lung cancer (NSCLC) patients undergoing radiation and immunotherapy. The key products and services to be delivered through this funding include: 1) Developing a clinical prototype of the TELOMESCAN assay with automated analysis to...
- The National Institute for Minority Health and Health Disparities awarded Biotarget DX LLC $295,924 on September 1, 2026, under the Minority Health and Health Disparities Research program (CFDA 93.307) to develop and validate a dual-platform plasma assay for early lung cancer detection in African American populations. Biotarget DX will integrate FirePlex and CRISPR-ELISA technologies to simultaneously detect ethnicity-specific non-coding RNAs and cytokines as biomarkers for lung cancer...
- Federal Grant Award Summary Illuminant Surgical Inc. received a $1,107,943 Project Grant from the National Cancer Institute under the Cancer Detection and Diagnosis Research Program (CFDA 93.394) awarded on September 12, 2025, with a completion date of August 31, 2027. This Phase II effort focuses on the continued development and validation of Skylight, a mixed-reality navigation platform designed to improve the accuracy and safety of image-guided biopsy procedures. The platform employs advanced...
- The National Cancer Institute awarded The University of Texas MD Anderson Cancer Center $645,186 on August 3, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop lung cell transplantation therapies for chemotherapy-induced pulmonary fibrosis in cancer patients. The research addresses a significant clinical gap: chemotherapy drugs including bleomycin, methotrexate, and oxaliplatin induce pulmonary fibrosis in cancer patients, and lung transplantation—the only currently...
- The National Cancer Institute awarded the University of California, Davis $409,141 on June 1, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop contrast-enhanced perfusion CT imaging as an alternative to current liver radioembolization workup procedures. The project addresses imaging optimization for selective internal radiation therapy (SIRT), a catheter-based treatment for liver cancer using radioactive yttrium-90 microspheres. Current clinical practice...